Substance Use Screening Documentation in a Psychiatric Visit: What to Capture, MDM Support, and Coding Implications

By Selam Koch, PMHNP-BC, founder of OneStep Scribe and practicing psychiatric nurse practitioner. Published July 2026.

Substance use screening is one of the most frequently performed, and most frequently under-documented, elements of a psychiatric visit. Whether you are conducting an initial evaluation, a follow-up, or a medication management check, the presence or absence of a documented substance use screen has direct consequences for your medical decision-making (MDM) level, your code selection, and your liability exposure.

This guide covers what to capture in a substance use screening note, how that information supports your MDM, and the specific coding implications that follow from complete versus incomplete documentation. The audience is practising clinicians, psychiatrists, psychiatric mental health nurse practitioners, and therapists, who document these encounters themselves or supervise others who do.

What to Capture in a Substance Use Screening

The documentation should reflect what was asked, how it was asked, and what the patient reported, including both use and non-use. The following elements should appear in your note for any psychiatric visit where substance use is clinically relevant, which is effectively every visit.

Substances Covered

Document screening for at least the major categories: alcohol, cannabis, stimulants (cocaine, amphetamines), opioids, sedative-hypnotics (benzodiazepines, z-drugs), hallucinogens, inhalants, and tobacco/nicotine. If the patient population or practice setting warrants, also document screening for prescription misuse (e.g., stimulant diversion, opioid overuse, benzodiazepine non-adherence).

Frequency, Quantity, and Route

For each substance endorsed, record the frequency (daily, weekly, monthly, etc.), the typical quantity (number of drinks, cigarettes, pills, bags, etc.), and the route of administration (oral, intranasal, intravenous, inhaled). This granularity allows the reader, and a reviewer, to assess severity without relying on vague terms like "social use" or "occasional."

Last Use and Pattern Changes

Document the date or time frame of last use for each substance. Also note any recent changes in pattern: escalation, reduction, attempts to cut down, or periods of abstinence. This is especially important when you are monitoring for withdrawal risk or planning pharmacotherapy that might interact with substances.

Functional Impact and Cravings

Record whether the patient reports any impairment in occupational, social, or other important areas of functioning due to substance use. Document any cravings or compulsive use patterns. This information supports the diagnostic assessment and directly informs your MDM around severity and treatment urgency.

Prior Treatment and Overdose History

If the patient has a history of substance use, document any prior treatment episodes (detox, residential, outpatient, medication-assisted treatment) and any history of overdose. Overdose history is a critical risk factor that elevates your MDM and should always be captured when present.

How Substance Use Screening Supports Medical Decision-Making

Medical decision-making in a psychiatric visit is driven by three pillars: diagnoses and management options, data reviewed, and risk. Substance use screening touches all three.

Diagnoses and Management Options

A positive screen introduces new diagnostic considerations (substance use disorders, substance-induced mood or anxiety disorders, withdrawal syndromes) and broadens the differential. Documenting the screen shows that you considered these possibilities. Even a negative screen supports the differential by ruling out a common confound. In either case, you have demonstrated diagnostic reasoning.

Data Reviewed

The substance use screen itself is a data point. When you document the specific questions asked and the patient's responses, that information counts toward the "data" pillar of MDM. If you use a structured screening instrument (e.g., AUDIT-C, DAST-10, CAGE-AID, or a locally adapted tool), document the instrument name and the score. This converts a subjective report into an objective data element that strengthens your MDM.

Risk Stratification

Substance use directly modifies risk in a psychiatric visit. A patient who uses alcohol heavily is at risk for withdrawal, suicide during intoxication, and drug interactions with prescribed psychotropics. A patient who uses opioids is at risk for respiratory depression if prescribed benzodiazepines. A patient who uses stimulants is at risk for cardiovascular events and psychotic symptoms. Documenting the screen and the patient's responses allows you to articulate the specific risks you considered and the plan you made to mitigate them. This is the core of risk-based MDM.

Coding Implications

Properly documented substance use screening can influence both your E/M code (for medication management or therapy visits) and your psychiatric diagnostic evaluation code (90791 or 90792). The key is that the screen must be more than a checkbox, it must be integrated into the assessment and plan.

E/M Coding (Outpatient Visit Codes)

For follow-up visits using 99212, 99215 (or the therapy add-on codes), substance use screening contributes to MDM in the following ways, which follow directly from what each of these levels actually requires:

• Straightforward MDM (99212): A negative screen with no risk factors and no change in management. Example: "Denies all substances. No intervention needed."
• Low MDM (99213): A positive screen that is mild, stable, and managed with brief counseling or a referral to a resource. Example: "Reports occasional cannabis use, once weekly. Advised on risks. No change to current treatment plan."
• Moderate MDM (99214): A positive screen that requires a change in medication, initiation of a substance use treatment, or monitoring for withdrawal or drug interaction. Example: "Reports daily alcohol use, 4, 5 drinks per day. Started naltrexone. Ordered LFTs. Discussed withdrawal risks and provided a safety plan."
• High MDM (99215): A positive screen with imminent risk such as active withdrawal, overdose history, or acute intoxication requiring emergency intervention or hospitalization.

Psychiatric Diagnostic Evaluation Codes (90791 and 90792)

For intake evaluations, substance use screening is an expected component of the history, and it carries more weight when the record shows where the substance history sits among the other intake domains. A thorough substance use history supports the medical necessity of the evaluation and justifies the complexity level. If the patient has a substance use disorder that complicates the diagnostic picture (e.g., mood symptoms that may be substance-induced), the documented screen directly supports the MDM for a more complex evaluation.

Common Documentation Pitfalls

The "Denies" Trap

A single word, "Denies", is the most common documentation error in substance use screening. It does not tell the reader what was denied, how the question was asked, or whether the screening was comprehensive. A reviewer or auditor cannot determine whether you screened for alcohol only or for all major categories. Write out what you asked and what the patient said.

Vague Quantifiers

Terms like "social use," "occasional," "recreational," and "minimal" are subjective and do not support MDM. Replace them with specific numbers and frequencies. "Occasional cannabis use" becomes "Cannabis use 2, 3 times per month, one joint per use." "Social drinking" becomes "Alcohol use 1, 2 drinks per week, usually wine with dinner."

Failure to Reassess

Substance use patterns change over time. For patients in ongoing treatment, document a re-screen at regular intervals, at minimum annually, and more frequently if there is a history of substance use or if you are prescribing controlled substances. The re-screen should be documented in the same level of detail as the initial screen.

Omitting Tobacco and Nicotine

Tobacco use is the leading cause of preventable death in the United States, and it is highly relevant to psychiatric care. Many psychiatric medications interact with nicotine metabolism (e.g., clozapine, olanzapine, caffeine). Documenting tobacco use status is a standard of care and a quality measure. Include it in every screen.

Putting It Together: A Documentation Template

The following template can be adapted for your notes. It is not a substitute for clinical judgment, but it provides a structure that ensures comprehensive documentation.

Special Considerations

Adolescents and Minors

When screening adolescents, document whether the screen was conducted with the patient alone (as recommended by confidentiality guidelines) and whether the parent or guardian was present. Be aware of state-specific confidentiality laws regarding minor consent for substance use treatment.

Pregnancy and Reproductive Planning

For patients of childbearing potential, document screening for alcohol, cannabis, and other substances in the context of pregnancy status and reproductive planning. This is a standard of care and has implications for both MDM and liability.

Patients on Controlled Substances

If you prescribe controlled substances, a documented substance use screen is part of your risk mitigation strategy, and it sits alongside the rest of documenting stimulant and benzodiazepine prescribing. Include urine drug test results when available, and document your discussion of the results with the patient. This protects both the patient and your practice.

Summary

Substance use screening documentation is not a formality. It is a clinical tool that supports your diagnostic reasoning, your risk assessment, and your code selection. By capturing the specific substances screened, the patient's responses in measurable terms, and your clinical interpretation and plan, you create a note that is defensible, useful to other clinicians, and aligned with billing requirements.

The additional two or three sentences it takes to move from "Denies" to a structured screen can be the difference between a note that gets downcoded and one that fully reflects the work you performed.

Frequently asked questions

How do I document a patient who declines substance use screening?

Document the decline as a clinical finding, not a gap. Note that you offered the screen, which categories you tried to cover, the patient's stance in neutral language, and any reason given. Then record what the decline changed: what you could not rule out, whether you deferred or adjusted a controlled substance prescription, which substitute sources you used, in particular your prescription drug monitoring program query and the date you ran it, plus outside records, pharmacy history or collateral where the patient permits, and when you plan to revisit. A documented decline shows a systematic assessment and gives your risk reasoning something concrete to rest on; an empty section shows nothing at all. It does not by itself set a visit level, which follows from what you actually managed. Payer policy varies, so verify with your own payer.

Does an AUDIT-C score by itself support billing a 99214?

No. A screening score is a data element, not a visit level. Outpatient E/M levels follow medical decision-making complexity or total time, so an AUDIT-C or DAST-10 result counts only through what it changes: the diagnoses you considered, the data you ordered or reviewed, and the risk you managed. Be careful with the data element. A score you collected in the visit is not uniformly accepted as reviewed data, and if you separately report the screening or the brief intervention, for example 96127 or the structured screening and brief intervention codes, that same work generally cannot also count toward the E/M data element. A score with brief counselling and no change in plan usually reads as low complexity; documentation quality decides whether the level you actually performed is supportable, it does not by itself raise the level. The same score with a new medication for alcohol use disorder, lab orders, withdrawal precautions and an interaction review more often reads as moderate. Payer policy varies, so verify level selection with your own payer.

What if a urine drug screen contradicts the patient's report?

Treat the discrepancy as clinical data and describe it neutrally. Record the test ordered, the collection date, the specific unexpected or absent findings, and the patient's account, without labelling the sample or the person. Immunoassay results are presumptive, so note whether you sent definitive testing; a screen alone does not establish use. Document plausible explanations on both sides: prescribed medications, over-the-counter agents and cross-reactivity for an unexpected positive; last dose timing, the assay cut-off, or a panel that never detects that drug for an expected negative. Then record the patient's explanation and what you decided about the controlled substance, monitoring, or treatment. That reasoning chain carries the risk element of your medical decision-making. Payer policy varies, so verify level selection with your own payer.

How do you document substance use for a patient in sustained remission?

Keep the narrative screen and the diagnosis together; neither stands in for the other. A coder can assign an in remission code only from your own explicit words, so state the disorder and the remission status in the assessment, for example alcohol use disorder, in sustained remission. Name the specifier you are using and why it fits, since sustained remission conventionally means at least twelve months without meeting criteria apart from craving, while early remission covers at least three months and less than twelve. Document the interval since last use and how it was corroborated where possible, whether the patient is receiving medication for opioid or alcohol use disorder, what supports the remission such as treatment engagement, peer support or a structured routine, and any recent stressors, cravings or brief returns to use. Record your monitoring plan and interaction concerns, for example prescribing a sedative-hypnotic to a patient with a history of alcohol use disorder. Remission still carries a risk of return to use, and documenting the reassessment keeps your reasoning grounded in current findings rather than a past label. Whether it raises the medical decision-making level depends on what you managed at the visit rather than on the remission status itself, so tie the note to the decision you made, for example continuing, changing or holding a medication, ordering labs, or increasing monitoring. Payer policy varies, so verify level selection with your own payer.